Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Assets (2020 - 2026)

Krystal Biotech's Assets history spans 7 years, with the latest figure at $1.4 billion for Q1 2026.

  • On a quarterly basis, Assets rose 30.02% to $1.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 billion, a 30.02% increase, with the full-year FY2025 number at $1.3 billion, up 26.33% from a year prior.
  • Assets hit $1.4 billion in Q1 2026 for Krystal Biotech, up from $1.3 billion in the prior quarter.
  • Over the last five years, Assets for KRYS hit a ceiling of $1.4 billion in Q1 2026 and a floor of $531.8 million in Q1 2023.
  • Historically, Assets has averaged $892.4 million across 5 years, with a median of $853.3 million in 2024.
  • Biggest five-year swings in Assets: dropped 13.78% in 2023 and later skyrocketed 60.44% in 2024.
  • Tracing KRYS's Assets over 5 years: stood at $558.4 million in 2022, then soared by 46.54% to $818.4 million in 2023, then grew by 29.02% to $1.1 billion in 2024, then grew by 26.33% to $1.3 billion in 2025, then grew by 4.74% to $1.4 billion in 2026.
  • Business Quant data shows Assets for KRYS at $1.4 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.